Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022159685 - SARS-COV-2 CORONAVIRUS ANTIBODIES AND USES THEREOF

Publication Number WO/2022/159685
Publication Date 28.07.2022
International Application No. PCT/US2022/013291
International Filing Date 21.01.2022
IPC
A61K 39/395 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 39/42 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
A61K 39/215 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
C07K 16/10 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
A61P 31/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
CPC
C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses ; , e.g. hepatitis E virus
C07K 2317/21
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
21from primates, e.g. man
C07K 2317/33
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
30characterized by aspects of specificity or valency
33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
C07K 2317/76
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
70characterized by effect upon binding to a cell or to an antigen
76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
C07K 2317/92
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
90characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applicants
  • VANDERBILT UNIVERSITY [US]/[US]
Inventors
  • GEORGIEV, Ivelin Stefanov
  • SHIAKOLAS, Andrea R.
  • KRAMER, Kevin J.
Agents
  • FENG, Yanjun
  • PRATHER, Donald M.
Priority Data
63/140,37922.01.2021US
63/165,86025.03.2021US
63/172,98109.04.2021US
63/175,24315.04.2021US
63/195,78902.06.2021US
63/299,60514.01.2022US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) SARS-COV-2 CORONAVIRUS ANTIBODIES AND USES THEREOF
(FR) ANTICORPS DE CORONAVIRUS DE SARS-COV-2 ET LEURS UTILISATIONS
Abstract
(EN) The present disclosure relates to antibodies and uses thereof for treating, preventing, and detecting coronavirus infection.
(FR) La présente divulgation concerne des anticorps et leurs utilisations pour le traitement, la prévention et la détection d'une infection par le coronavirus.
Latest bibliographic data on file with the International Bureau